Researchers at Thomas Jefferson University have found a new way to help. Their study showed that using two diabetes ...

This discovery shows that a thoughtful combination of medicines can make a big difference in treating complex cases of Type 2 ...

There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and ...

GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy ...

LIBERATE-1 is a first-in-human study of NPM-115, the Company’s miniature, twice-yearly GLP-1 (exenatide) implant under ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc.

Smartwatches offer “great promise” for encouraging people with newly diagnosed type 2 diabetes to maintain a good exercise regime, a recent study has highlighted. International researchers have found ...

In the mid-1990s, New York-based scientist John Eng discovered that the hormone exenatide – isolated from the Gila monster, a venomous lizard – mimicked the actions of GLP-1. So Drucker set out to ...

Low levels of soluble neuropilin-1 (sNRP-1) were associated with depression in patients with newly diagnosed type 2 diabetes (T2D), with the association remaining consistent across all age groups ...

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...

Together, these data demonstrate the versatility of the NanoPortal technology beyond NPM-115 (exenatide implant) and provide significant encouragement for continued development of each program.

Drivers with diabetes are safer on the road if they are using a continuous glucose monitoring device that alerts them when their blood sugar levels drop, new evidence has shown. Researchers from Japan ...